13-Methyltetradecanoic acid
Based on 1 Customer Validation
13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid with potent anticancer effects. 13-Methyltetradecanoic acid induces apoptosis in many types of human cancer cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.97%
- CAS No.: 2485-71-4
- 화학식: C15H30O2
- 분자량:242.40
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-126477
NNKNicotine-nitrosated Derivative -
HY-126477R
NNK (Standard)Nicotine-nitrosated Derivative -
HY-W116576
3-MethoxycatecholCombretastatin Intermediate -
HY-W116576R
3-Methoxycatechol (Standard)Combretastatin Intermediate -
HY-119558
Bromacil -
HY-127143
Sterculic acidSCD1 Inhibitor -
HY-121940
14-Methylhexadecanoic acidBiochemical Assay Reagent -
HY-W127341
Phytanic acid methyl esterBiochemical Assay Reagent -
HY-119558R
Bromacil (Standard) -
HY-N7824
15-Methylpalmitic acidBiochemical Assay Reagent -
HY-130357
15(S)-HETE EthanolamideCannabinoid Analog
Biological Activity
제품 설명
In Vitro
13-Methyltetradecanoic acid (13-MTD; 0-140 μg/mL; 12-24 hours) inhibits cell viability and proliferation in human bladder cancer cells by inducing apoptosis[1].
13-Methyltetradecanoic acid (13-MTD; 70 μg/mL; 2-48 hours) treatments results in significant accumulation of cells with sub-G1 DNA content in a time-dependent manner, with the proportion of sub-G1 phase DNA content ranging from 9.25% to 85.3% over 2-48 hours[1].
13-Methyltetradecanoic acid (13-MTD; 70 μg/mL; 2-24 hours) down-regulates Bcl-2 and up-regulates Bax. This promotes mitochondrial dysfunction, leading to the release of cytochrome c from the mitochondria to the cytoplasm, as well as the proteolytic activation of caspases. 13-Methyltetradecanoic acid down-regulates AKT phosphorylation and activates phosphorylation of p38 and c-Jun N-terminal kinase (JNK)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Bladder cancer cell lines T24, 5637, and UM-UC-3
-
Concentration:0 μg/mL, 35 μg/mL, 70 μg/mL, 105 μg/mL, and 140 μg/mL
-
Incubation Time:12 hours, 24 hours
-
Result:Inhibition of cell viability in a dose- and time-dependent manner.
-
Cell Line:Bladder cancer cell lines T24, 5637, and UM-UC-3
-
Concentration:70 μg/mL
-
Incubation Time:2 hours, 8 hours, 24 hours, or 48 hours
-
Result:Resulted in significant accumulation of cells with sub-G1 DNA content in a time-dependent manner.
-
Cell Line:T24, 5637, and UM-UC-3 cells
-
Concentration:70 μg/mL
-
Incubation Time:2 hours, 8 hours, 24 hours
-
Result:Down-regulated Bcl-2 and up-regulated Bax, and down-regulated AKT phosphorylation and activated phosphorylation of p38 and c-Jun N-terminal kinase (JNK).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C nude mice injected with Jurkat lymphoma cells[2]
-
Dosage:70 mg/kg/day
-
Administration:Oral gavage; daily; for 30 days
-
Result:Effectively inhibited the growth in vivo in a xenograft model.
Chemical Information
-
CAS No. 2485-71-4
-
Appearance Solid
-
분자량 242.40
-
화학식 C15H30O2
-
Color White to off-white
-
SMILES
CC(C)CCCCCCCCCCCC(O)=O
-
Synonyms
13-MTD; 13-Methylmyristic acid
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
In Vitro:
Ethanol : ≥ 100 mg/mL (412.54 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Protocol
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
순도&문서
-
Data Sheet (271 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tianxin Lin, et al. 13-Methyltetradecanoic acid induces mitochondrial-mediated apoptosis in human bladder cancer cells. Urol Oncol. May-Jun 2012;30(3):339-45. [Content Brief]
[2]. Qingqing Cai, et al. 13-methyltetradecanoic acid exhibits anti-tumor activity on T-cell lymphomas in vitro and in vivo by down-regulating p-AKT and activating caspase-3. PLoS One. 2013 Jun 7;8(6):e65308. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 4.1254 mL | 20.6271 mL | 41.2541 mL | 103.1353 mL |
| 5 mM | 0.8251 mL | 4.1254 mL | 8.2508 mL | 20.6271 mL | |
| 10 mM | 0.4125 mL | 2.0627 mL | 4.1254 mL | 10.3135 mL | |
| 15 mM | 0.2750 mL | 1.3751 mL | 2.7503 mL | 6.8757 mL | |
| 20 mM | 0.2063 mL | 1.0314 mL | 2.0627 mL | 5.1568 mL | |
| 25 mM | 0.1650 mL | 0.8251 mL | 1.6502 mL | 4.1254 mL | |
| 30 mM | 0.1375 mL | 0.6876 mL | 1.3751 mL | 3.4378 mL | |
| 40 mM | 0.1031 mL | 0.5157 mL | 1.0314 mL | 2.5784 mL | |
| 50 mM | 0.0825 mL | 0.4125 mL | 0.8251 mL | 2.0627 mL | |
| 60 mM | 0.0688 mL | 0.3438 mL | 0.6876 mL | 1.7189 mL | |
| 80 mM | 0.0516 mL | 0.2578 mL | 0.5157 mL | 1.2892 mL | |
| 100 mM | 0.0413 mL | 0.2063 mL | 0.4125 mL | 1.0314 mL |
13-Methyltetradecanoic acid Related Classifications
HY-131503 Related Classifications
Powered by Bioz